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Edited by Robert BaroukiAbstract This study tests the hypothesis that islet peroxisome
proliferator-activated receptor alpha (PPARa) inﬂuences insulin
secretion. Freshly isolated islets of normoglycemic PPARa-null
mice display no major alteration of glucose-stimulated insulin
release. However, after 24 h of culture in high glucose,
PPARa-null islets exhibit elevated basal insulin secretion and
fail to increase insulin mRNA. 24-h culture with palmitate repli-
cates this phenotype in wild-type islets. The data suggest that
PPARa is needed to ensure appropriate insulin secretory
response in situation of short-term hyperglycemia, likely by
maintaining islet lipid homeostasis. As such, islet PPARa could
contribute to delay the progression of type 2 diabetes.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The peroxisome proliferator-activated receptor alpha
(PPARa) is a ligand-activated nuclear transcription factor
that upregulates genes of the FA b-oxidation pathways in
various tissues [1,2]. A series of recent studies show that
PPARa is a major determinant of FA oxidation in rodent is-
lets and INS b-cells [3–8]. As such, PPARa has the potential
to inﬂuence islet lipid content and, in turn, insulin release.
To address the role of PPARa in b-cell secretory function,
we have used the PPARa-null mouse model. Our initial
hypothesis was that PPARa-deﬁciency would lead to lipid
accumulation in the islet and impair insulin secretion. Exper-
iments showing that glucose-stimulated insulin secretion
(GSIS) was not altered in freshly isolated islets from
C57BL/6N PPARa-null mice appeared to disprove this
hypothesis [9]. At variance with these observations, Gremlich*Corresponding author. Fax: +33 1 40 51 85 86.
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PPARa-null mice, suggesting that islet PPARa controls neg-
atively insulin release. Accordingly, overexpression of
PPARa in INS b-cell causes a signiﬁcant reduction in GSIS
[7]. However, the ﬁnding that PPARa is profoundly down-
regulated in islets of type 2 diabetic Zucker fatty rats is at
odds with a negative eﬀect of PPARa on insulin secretion
[3]. These observations do not allow a clear-cut conclusion
on whether and how PPARa aﬀects b-cell secretory function.
This prompted us to reevaluate the capacity of PPARa-null
islets to produce insulin, in situation of normal or altered
glucose homeostasis.2. Materials and methods
2.1. Animals
This study was conducted according to the Guidelines for the Care
and Use of Experimental Animals. Male PPARa-null mice on either
pure Sv129 [10] or 10 generations backcrossed C57BL/6N [11] genetic
backgrounds were used with similar results. Mice were maintained un-
der a constant light–dark cycle (light from 7:00 am to 7:00 pm) and re-
ceived a standard diet (UAR AO4, Epinay/Seine, France) or a high-fat
diet containing hydrogenated coconut oil (29%, w/w) for 22 weeks [12].
Blood samples were obtained from the orbital sinus between 9:00 and
10:00 am. Serum was separated and stored at 20 C until use.
2.2. Serum assays
Plasma insulin was determined using an ELISA kit (Eurobio, Cour-
taboeuf, France). Leptin and adiponectin plasma levels were measured
by radio-immunoassay with commercial kits from Linco Research (St.
Louis, MO, USA). Blood glucose was determined by a glucose ana-
lyzer (Beckman Coulter, Fullerton, CA, USA).
2.3. Islet isolation and static incubations
Following pancreas digestion by intraductal injection of collagenase,
isolated islets were puriﬁed by double-hand picking and incubated in 1-
h static incubation with 2.8 (basal) or 16.7 mM glucose [13]. Islets from
1 to 2 mice of each genotype were used per experiment. Insulin concen-
trations in the medium were determined by radio-immunoassay (SB
INS 15, CIS Bio International, Gif/Yvette, France).
2.4. Islet culture
After an overnight culture in RPMI 1640 containing 10% fetal calf
serum, 11.1 mM glucose and antibiotics, islets were resuspended in
fresh media and incubated in RPMI containing 2.8, 16.7 mM glucose
or 16.7 mM glucose with palmitate (0.5 mM) at a molar ratio of palm-
itate to bovine serum albumin of 5:1 [14]. After 24-h of culture, islets
were incubated in 1-h static incubation as above.ation of European Biochemical Societies.
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Total RNA was extracted from 80 to 120 cultured islets by the guan-
idinium thiocyanate method [15]. First-strand cDNA was reverse tran-
scribed from total RNA using random hexamers as primers, according
to the MMLV ﬁrst-strand cDNA synthesis protocol (Promega, Lyon,
France). Relative quantiﬁcation of cDNA was performed by real-time
quantitative PCR, using the Taqman probe approach, on a Light Cy-
cler instrument (Roche Diagnostics, Meylan, France). Insulin primers
and probe were as follows: Insulin Reverse: 5 0 CTC CAG TGC CAA
GGT CTG AA 3 0; Insulin Forward: 5 0 GTG GCT TCT TCT ACA
CAC CCA T 3 0; Insulin Probe: 5 0 TTG TGC CAC TTG TGG GTC
CTC CAC 3 0. PCR was performed for 45 cycles with 10 s at 95 C,
10 s at 60 C and 10 s at 72 C. 18 s rRNA was quantiﬁed for normal-
ization.
2.6. Statistical analysis
Data are shown as mean ± S.E.M. Comparison between groups
were performed by Students t test or, for multiple comparisons,
one-way ANOVA with Tukeys post testing. A diﬀerence at P < 0.05
was considered statistically signiﬁcant.Fig. 1. Insulin secretion in freshly isolated islets from chow-fed WT
and PPARa-null (KO) mice. Results are means ± S.E.M. of ﬁve to
eight separate incubations. Insulin release was signiﬁcantly higher than
at 2.8 mM glucose for each treatment whatever the PPARa genotype
(P < 0.05 by paired Students t test). Addition of palmitate, carbachol
or IBMX signiﬁcantly potentiated insulin release at 16.7 mM glucose
in both groups (P < 0.05 by paired Students t test). *P < 0.05 versus
WT by Students t test.3. Results
Islet function was analyzed in both C57BL/6N and Sv129
PPARa-null mice with similar results (data not shown).
PPARa-deﬁciency did not signiﬁcantly alter basal or GSIS in
freshly isolated islets (Fig. 1). Addition of 1 mM palmitate
ampliﬁed GSIS by 2-fold in both wild-type (WT) and
PPARa-null islets, indicating that PPARa signaling is not re-
quired for acute stimulatory eﬀect of FA on GSIS. Activation
of the phospholipase C pathway by carbachol also potentiated
GSIS to the same extend (·4) in both genotypes. By contrast,
GSIS potentiation by 3-isobutyl 1-methylxanthine (IBMX)
that increases cellular cAMP through adenylate cyclase activa-
tion, was less eﬃcient in PPARa-null islets (·4) than in WT is-
lets (·7). Further experiments are needed to determine whether
activation of PPARa by PKA [16] is required for the full eﬀect
of IBMX on insulin release.
To test insulin secretory response of PPARa-null islets in sit-
uation of altered glucose homeostasis, mice were fed a high-fat
diet. This nutritional challenge is known to induce peripheral
insulin resistance and compensatory increase in insulin release.0
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Fig. 2. Eﬀect of high-fat feeding on insulin secretion in freshly isolated islets
seven separate incubations. Insulin release at 16.7 mM was signiﬁcantly high
(P < 0.05 by one-way ANOVA). *P < 0.05 versus all other bars by one-wayHigh-fat feeding enhanced GSIS (·3) in islets from WT mice
but was without eﬀect in PPARa-null mice (Fig. 2). Although
both WT and PPARa-null mice responded to high-fat by
increasing adiposity, as indicated by elevation of plasma leptin,
high-fat feeding failed to increase glucose and insulin circulat-
ing levels in PPARa-null mice (Table 1). Moreover, adiponec-
tinemia was reduced by twice in hyperinsulinemic WT mice
and unchanged in normoinsulinemic high-fat fed PPARa-null
mice. These data indicate that PPARa-null mice do not
develop diet-induced insulin resistance, a situation likely to
preclude islet compensatory increase in insulin release.
Thus, to assess the impact of PPARa deletion under condi-
tions of hyperglycemia, islets were cultured for 24 h in high or
low glucose. In low glucose, WT and PPARa-null islets dis-
played similar rates of insulin secretion (Fig. 3A), with a secre-8.3 mM 16.7 mM
*
*
from WT and PPARa-null (KO) mice. Results are means ± S.E.M. of
er than at 2.8 mM glucose whatever the diet and the PPARa genotype
ANOVA.
Table 1
Eﬀect of 22 weeks of high-fat feeding in Sv129 WT and PPARa-null mice
Wild-type mice PPARa-null mice
Standard diet (n = 9) High-fat diet (n = 9) Standard diet (n = 8) High-fat diet (n = 9)
Body weight (g) 30.0 ± 0.64 33.7 ± 0.81b 30.2 ± 0.83 29.2 ± 0.71a
Glucose (mmol/l) 6.9 ± 0.24 7.8 ± 0.35b 6.9 ± 0.37 4.4 ± 0.32a,b
Insulin (pmol/l) 52 ± 5.4 132 ± 28.1b 78 ± 9.0a 81 ± 14.8
Leptin (ng/ml) 3.5 ± 0.26 7.2 ± 1.49b 4.7 ± 0.77 8.8 ± 1.30b
Adiponectin (lg/ml) 33.8 ± 3.84 13.8 ± 3.60b 28.0 ± 2.37 26.2 ± 4.13a
Data are means ± S.E.M.
aP < 0.05 versus WT.
bP < 0.05 versus chow diet by Students t test.
Fig. 4. Insulin gene expression in 24-h cultured islets from WT and
PPARa-null (KO) mice. Insulin mRNA was measured in islets
cultured for 24-h in presence of 2.8 mM glucose (n = 4), 16.7 mM
glucose (n = 5) or 16.7 mM glucose plus 0.5 mM palmitate (n = 4).
Results are means ± S.E.M. *P < 0.05 versus all other bars by one-way
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to high glucose increased insulin secretion index up to 10 times
basal, due to elevated GSIS with no change in basal insulin re-
lease. In PPARa-null islets, however, although GSIS increased
to the same level as in WT islets, culture in high glucose in-
creased basal insulin secretion, resulting in a 3-fold reduction
of secretion index. Similar to PPARa-deﬁciency, addition of
palmitate to the high glucose medium increased basal insulin
secretion in WT islets, thereby reducing insulin secretion index
to a value similar as in PPARa-null islets. Of note, palmitate
was without signiﬁcant eﬀect as compared to glucose alone
in PPARa-null islets.
The regulation of insulin gene expression was analyzed after
24-h of culture in low or high glucose, without or with palmi-
tate. In WT islets, insulin mRNA level was markedly increased
(·6) by exposure to high glucose and reduced 4-fold by palm-
itate, thereby following a closely similar pattern of change as
insulin secretion index. This regulation was totally blunted in
PPARa-null islets (Fig. 4).
ANOVA.4. Discussion
The lack of major alteration of insulin release in PPARa-
null islets suggests that PPARa is unlikely to play a majorFig. 3. Eﬀect of 24-h culture in low or high glucose without or with palmitate
Basal (2.8 mM) and glucose induced (16.7 mM) insulin secretion in 1-h incu
16.7 mM glucose plus 0.5 mM palmitate (n = 5). (B) Insulin secretion inde
incubation in 16.7 over 2.8 mM glucose. Results are means ± S.E.M. Bars
ANOVA).role in b-cell insulin secretory function in normal, insulin sen-
sitive mice. However, this does not exclude a modulatory role, on insulin secretion in islets fromWT and PPARa-null (KO) mice. (A)
bation of islets cultured in 2.8 mM (n = 3), 16.7 mM glucose (n = 5) or
x calculated as the fold stimulation of insulin release induced by 1-h
with diﬀerent letters are signiﬁcantly diﬀerent (P < 0.05 by one-way
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High-fat feeding is known to promote islet hypertrophy in re-
sponse to increased endogenous demand for insulin produc-
tion [17], although enhanced insulin secretion is not always
observed ex vivo [9,18,19]. Here, GSIS increased 3-fold in is-
lets of high-fat fed Sv129 WT mice but not in PPARa-null
mice. These observations are surprising, since it was antici-
pated that high-fat feeding would favor excessive lipid accu-
mulation in PPARa-null islets and impair GSIS. The most
likely explanation is that, since PPARa-null mice are pro-
tected from diet-induced insulin resistance [9] (present study),
the compensatory changes that normally occur in islets under
high-fat feeding did not take place in PPARa-null mice. This
prompted us to examine the response of PPARa-null islets to
elevated glucose levels in vitro, in the absence of the con-
founding eﬀect of diﬀerence in insulin sensitivity between
both genotypes.
We choose to culture islets for 24 h in high glucose to
reproduce a situation of short-term hyperglycemia. Our data
show that PPARa is needed to ensure correct insulin secretory
response in islets exposed to elevated glucose. In normal islets,
this adaptive process relied on increased GSIS with no change
in basal insulin release. In absence of PPARa, however, eleva-
tion of basal insulin secretion markedly reduced the ampli-
tude of insulin response. A similar increase in insulin
secretion at low glucose was produced by exogenous palmi-
tate in WT islets, in agreement with previous observations
in rat islets [20]. Moreover, the eﬀects of palmitate and
PPARa deﬁciency were not additive, suggesting a common
mechanism. Studies by the group of Leahy have shown that
24 h of culture with palmitate increased hexokinase activity
in rat islets, by lowering the concentration of its allosteric
inhibitor, glucose-6-phosphate [20–22]. As a result, the kinet-
ics of glucose entry into the metabolic pathway is altered,
leading to increased insulin secretion at low glucose concen-
tration. Islet PPARa could contribute to minor this lipid-
dependent left-shift of glucose concentration/insulin secretion
relationship.
Our data further show that PPARa is needed for the induc-
tion of insulin mRNA, which is part of the b-cell response to
hyperglycemia [23]. The similar inhibitory eﬀect of PPARa
deﬁciency and palmitate suggests that lipid molecule(s) medi-
ate insulin gene downregulation in PPARa-null islets exposed
to high glucose. It was recently shown that palmitate inhibi-
tion of insulin gene expression is mediated at the transcrip-
tional level via ceramide [24]. This raises the hypothesis
that induction of insulin gene by hyperglycemia requires a
PPARa-dependent mechanism to lower islet ceramide. Inter-
estingly, PPARa activation reduces neutral sphingomyelinase
activity in primary human macrophages, suggesting that
PPARa might interfere negatively with the production of
ceramide [25].
The question arises whether activation of PPARa signaling
ameliorates b-cell function in insulin-resistant states. Amelio-
ration of functional and morphometric parameters of pancre-
atic islets in insulin resistant rodents treated with ﬁbrates
supports this hypothesis [19,26,27]. However, since ﬁbrates en-
hance whole body insulin sensitivity [26,28,29], this eﬀect, by
itself, might be suﬃcient to ameliorate b-cell sensitivity to glu-
cose [30]. Thus, it is not clear whether beneﬁcial eﬀects of ﬁ-
brates result from either peripheral insulin sensitization,
direct activation of PPARa signaling in the islets, or both.In conclusion, PPARa signaling does not appear essential
for the control of insulin secretion in normoglycemia, but is
needed for the b-cell adaptive response to hyperglycemia.
The role of PPARa could be to ensure that lipid products,
which remain to be identiﬁed, do not jeopardize insulin re-
sponse. This function of PPARa might be crucial to sustain
b-cell secretory capacity during the early phases of type 2 dia-
betes, when the b-cells are submitted to post-prandial episodes
of hyperglycemia and need to implement compensatory
changes in the face of insulin resistance to delay the progres-
sion to overt diabetes.
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